Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Work In Process for 4 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 115.33% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 115.33% year-over-year, with the annual reading at $6.3 million for FY2025, 115.33% up from the prior year.
  • Work In Process for Q4 2025 was $6.3 million at Gyre Therapeutics, up from $4.4 million in the prior quarter.
  • The five-year high for Work In Process was $6.3 million in Q4 2025, with the low at $2.0 million in Q4 2023.
  • Average Work In Process over 4 years is $3.6 million, with a median of $3.5 million recorded in 2024.
  • The sharpest move saw Work In Process plummeted 45.54% in 2023, then skyrocketed 115.33% in 2025.
  • Over 4 years, Work In Process stood at $3.7 million in 2022, then tumbled by 45.54% to $2.0 million in 2023, then skyrocketed by 46.67% to $2.9 million in 2024, then surged by 115.33% to $6.3 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $6.3 million, $4.4 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.